Federal Cannabis Rescheduling: What the Move to Schedule III Means for the Industry

Federal Cannabis Rescheduling: What the Move to Schedule III Means for Operators
Cannabis Policy

Federal Cannabis Rescheduling: What the Move to Schedule III Means for Operators Right Now

The federal government has taken its most significant step in cannabis policy in over 50 years. Here's what actually happened, what the industry is saying, and what it means for your business — with eyes wide open on what's still uncertain.

What happened

On December 18, 2025, President Trump signed an executive order directing Attorney General Pam Bondi to expedite the reclassification of cannabis from Schedule I to Schedule III of the Controlled Substances Act. The move builds on a years-long policy review that began under the Biden administration — including a 2023 HHS recommendation, a May 2024 DEA proposed rule, and nearly 43,000 public comments — all of which stalled before a final rule was ever issued.

Then, in April 2026, the Department of Justice and DEA went further: they issued an immediate order placing FDA-approved cannabis products and state-licensed medical cannabis products into Schedule III now, while initiating an expedited administrative hearing process beginning June 29, 2026 to evaluate broader cannabis rescheduling.

Key distinction

The executive order itself does not move cannabis to Schedule III. It instructs DOJ and DEA to complete the rulemaking. Cannabis officially remains Schedule I until a final rule is issued and takes effect.

Initial industry reactions

Reaction from the cannabis industry has ranged from cautious optimism to outright celebration — with some skepticism from policy analysts who have watched similar moments stall before.

Rescheduling unlocks the removal of 280E, fundamentally reshaping cash flows, balance sheets, and valuation frameworks. With normalized tax treatment, the industry can finally operate like a real consumer or healthcare category.

— Karan Wadhera, Casa Verde Capital co-founder

This is not about legalization — it's about legitimacy. Removing 280E allows compliant, state-licensed operators to reinvest in growth, innovation and workforce development across the nearly half-million Americans employed in this industry.

— Michelle Rutter Friberg, National Cannabis Industry Association

Skeptics point to a real tension: while Trump's executive order signals support for rescheduling, agencies within his own administration — including the DEA — had, as recently as late 2025, quietly rescinded Biden-era policies of non-prosecution for personal marijuana possession. Federal marijuana arrests have continued, and some analysts view the executive order as largely symbolic until a final rule takes effect.

Immediate benefits for cannabis operators

These are the impacts operators can begin planning around — with the caveat that most don't take full legal effect until a final rule is issued.

Immediate / near-term impact
1
End of IRC 280E (prospective)
Once a final rule takes effect, cannabis businesses will no longer be denied ordinary business deductions — rent, payroll, marketing, professional fees. Some operators currently face effective federal tax rates of 70%+. This is the single largest financial impact in the industry's history.
2
Improved cash flow and reinvestment capacity
Maryland cannabis retailers alone are projected to save an average of $805,000 per store annually if 280E is removed. Freed capital can be redirected to operations, debt reduction, or workforce investment.
3
Institutional investor signal
Rescheduling is being widely treated as a "de-risking signal" for capital markets. Institutional investors who have been sidelined by federal Schedule I status may begin re-evaluating cannabis exposure.
4
Federal recognition of medical value
Schedule III classification formally acknowledges that cannabis has accepted medical use — a legal and reputational shift after 55 years of Schedule I designation alongside heroin and LSD.
5
Reduced DEA research barriers
Schedule III substances face significantly less burdensome DEA requirements for research. Expanded clinical study pipelines could validate new medical applications and strengthen insurance coverage arguments.
6
Tax planning and restructuring window
The period between now and a final rule gives operators time to revisit entity structures. Strategies adopted to minimize 280E exposure — such as C-Corp elections — may no longer be optimal in a post-280E world.

Long-term benefits for cannabis operators

Long-term / structural impact
1
Improved banking and financial services access
While rescheduling does not fully resolve banking access, Schedule III status may make banks and payment processors more willing to serve cannabis businesses — reducing reliance on cash-only operations and improving treasury management.
2
Potential trademark and IP protections
Federal Schedule III status opens a potential path to US trademark protections — currently unavailable to cannabis brands operating under Schedule I — providing long-term brand equity protection.
3
Expanded marketing and advertising opportunities
With 280E deductions restored, marketing spending becomes economically viable at scale. National advertising channels that currently exclude cannabis may begin accepting cannabis advertising as federal posture shifts.
4
Improved competitive position against illicit market
Licensed operators have historically been at an extreme tax disadvantage versus unlicensed competitors who pay no 280E. Lower effective tax rates improve licensed operators' pricing power and competitive footing.
5
Valuation uplift and M&A activity
Normalized tax treatment will meaningfully reprice cannabis company valuations. Improved EBITDA multiples, better balance sheets, and institutional capital access should accelerate M&A activity and consolidation.
6
Platform for future federal reform
Most policy analysts view Schedule III as a stepping stone. Federal legalization, interstate commerce, and full SAFE Banking Act passage become significantly more achievable political and regulatory targets once Schedule I is broken.

What's still uncertain — and why it matters

Key uncertainties
!
280E relief is not retroactive
Tax experts broadly agree that relief applies prospectively only — from the date a final rule takes effect. 2025 taxes are subject to 280E. Some operators may attempt amended returns, but IRS precedent strongly disfavors retroactive relief.
!
Timeline remains unclear
The administrative hearing beginning June 29, 2026 is a starting point, not a finish line. Depending on proceedings, litigation, and appeals, finalization ranges from late 2026 in an optimistic scenario to 2027–2028 if courts or administrative processes delay it.
!
State-legal adult-use markets remain federally illegal
Rescheduling does not legalize cannabis federally. State-licensed recreational dispensaries dispensing without an FDA-approved prescription still technically violate federal law. This tension does not resolve with Schedule III alone.
!
Congress could preserve or recreate 280E
Proposals exist in Congress to amend the tax code to explicitly preserve 280E-style disallowances even after rescheduling. This is a non-trivial risk and merits close monitoring through 2026.
!
State taxes may offset federal savings
Some states may view federal 280E relief as an opportunity to increase their own cannabis excise taxes — partially or fully offsetting the financial gains operators expect from rescheduling.
!
Stock exchange listings still prohibited
US-listed exchanges (NYSE, Nasdaq) cannot list cannabis companies while cannabis remains federally illegal regardless of schedule. Full capital markets access requires additional legislative action beyond rescheduling.

What comes next: the rescheduling timeline

  • Completed
    Trump executive order signed — Dec 18, 2025
    Directed DOJ/DEA to expedite rescheduling to Schedule III.
  • Completed
    DOJ/DEA partial interim order — April 2026
    FDA-approved cannabis products and state-licensed medical cannabis immediately placed in Schedule III. Full rescheduling proceedings announced.
  • Upcoming
    Administrative hearing begins — June 29, 2026
    Formal hearing on broader cannabis rescheduling. Testimony, evidence, and cross-examination. This is a legal proceeding, not a policy debate.
  • Pending
    ALJ recommended decision
    Administrative law judge issues findings. Parties may file exceptions before the record is certified to the DEA Administrator.
  • Pending
    DEA Administrator final order published
    Best case: late 2026. Realistic planning baseline: 2027. Delayed scenario (court stay or appeals): 2028+.
  • Pending
    Final rule effective date — 280E relief begins
    The moment operators can begin deducting ordinary business expenses. 30-day minimum from publication. Subject to Congressional Review Act challenge window.
  • Future
    Potential litigation and court challenges
    Legalization opponents have vowed to sue. Court challenges could stay the effective date and delay relief further.
Planning guidance for operators

Do not assume 280E relief for your 2025 or 2026 tax filings until a final rule is effective. Model multiple scenarios — rescheduling effective mid-2026, 2027, and delayed past 2027. Revisit entity structure and cost allocation strategies now, before a final rule locks in your position. Work with your cannabis CPA on scenario-based tax planning.

MindfulCPAs specializes in cannabis tax strategy, 280E planning, and post-rescheduling advisory services. If you're a cannabis operator, founder, or cultivator preparing for the Schedule III transition, now is the time to model your tax position and restructure before a final rule takes effect. Reach out to start a planning conversation.